Skip to content

    CORONA Remedies Limited

    CORONA
    Healthcare·12 May 2026
    Management Summary

    CORONA Remedies Limited delivered a robust performance in Q4 and FY26, significantly outpacing industry growth with strong revenue and PAT expansion. The company's strategic focus on chronic and semi-chronic therapies, coupled with successful acquisitions and new product launches, positions it for continued growth, despite a temporary dip in Q4 margins attributed to growth investments.

    Highlights

    5

    • FY26 Revenue grew 17.3% YoY to INR 1,403 crores, outperforming IPM growth of 8.6%.

    • FY26 Adjusted PAT increased 33.4% YoY to INR 199 crores.

    • FY26 EBITDA margin expanded 80bps to 20.9%.

    • Declared a 100% dividend, equivalent to INR 10 per share for FY26.

    • Successfully completed two strategic acquisitions (Wokadine and Bayer's Portfolio) and entered the biosimilars market with three new product launches.

    Concerns

    1

    • Q4 FY26 EBITDA margin declined by 90bps to 17.6% due to increased employee costs from new division additions and higher R&D spend.

    Key financials

    Metrics

    11

    Periods

    2

    Q4 FY26

    4
    • Revenue
      ₹353 Cr
      YoY+20.2%
    • EBITDA
      ₹62 Cr
      YoY+14.4%
    • EBITDA Margin
      17.6%
    • PAT
      ₹45 Cr
      YoY+44%

    FY26

    7
    • Revenue
      ₹1,403 Cr
      YoY+17.3%
    • EBITDA
      ₹293 Cr
      YoY+22.3%
    • EBITDA Margin
      20.9%
    • Adjusted PAT
      ₹199 Cr
      YoY+33.4%
    • CFO
      ₹229 Cr

    Segment breakdown

    Q4 FY26 Domestic Business
    18.3% Growth
    Q4 FY26 International Business
    70% Growth
    FY26 Domestic/India Business
    16.8% Growth96% Contribution to Total Revenue
    FY26 International Business
    29.5% Growth
    FY26 Chronic Segment
    71.9% Contribution to Total Revenue
    List

    Capital allocation

    5
    high confidence
    CategoryHeadline
    Debt

    Gross ₹143 crores · Net ₹-15 crores

    Dividend

    ₹10/share (final)

    M&A

    Wokadine

    acquisition · closed

    M&A

    Bayer's Portfolio

    acquisition · integrated

    Liquidity

    Liquidity disclosed

    Company maintains a net cash surplus position.

    Guidance & targets

    12
    CategoryTargetPriority
    Revenue
    Organic Revenue Growth
    15% plus
    		High
    Revenue
    Acquired Brand Revenue Growth
    25%
    		High
    Revenue
    Revenue Growth
    15%
    		High
    Revenue
    Organic Domestic Revenue Growth
    15%
    		High
    Revenue
    International Business Growth
    8-9%
    		High
    Revenue
    Wokadine Revenue Growth
    25%
    		High
    Profitability
    PAT Growth
    20% plus
    		High
    Profitability
    PAT Growth
    20%
    		High
    Margin
    Gross Margins
    80%
    		High
    Margin
    Wokadine Gross Margin Correction
    400 basis points
    		High
    Industry Growth (IPM)
    Overall IPM Growth
    10% to 10.3%
    		High
    Volume
    Company Volume Growth
    3x to 4x IPM volume growth
    		High

    What to watch in Q1 FY27

    5

    Q1 FY27 EBITDA Margin

    Next quarter (Q1 FY27 results)
    Current17.6% (Q4 FY26)
    TargetImprovement towards FY26 average of 20.9%

    Why it matters

    To assess if the Q4 margin dip was temporary due to growth investments or indicates a more structural trend.

    EBITDA margin declined by around 90bps and stood at 17.6%. Decline was on account of an increase in employee cost with respect to the addition of two new divisions... However, let me tell you all, these are all growth investments which will reap benefits for the future period.

    Risks & concerns

    2
    RiskSeverity

    Q4 EBITDA margin decline due to growth investments

    Q4 FY26 EBITDA margin declined by 90bps to 17.6% due to increased employee costs from new division additions and higher R&D spend, which management views as growth investments. — Management acknowledged

    medium

    Potential impact of rising Raw Material (RM) costs and geopolitical events (Middle East)

    Management noted that oil and other parameters impact APIs, and while they have 90-120 days of inventory, it's too early to quantify the long-term impact if the situation persists. — Analyst acknowledged

    medium

    Q&A highlights

    8

    “Our philosophy is to grow 15% on a revenue and 20% on a PAT basis on a year-on-year basis for coming 3 to 5 years down the line. ... we would be maintaining the gross margins at the range of 80% in the coming years down the line.”

    Clarifies management's long-term margin philosophy and commitment to 80% gross margins despite a Q4 dip, aligning with revenue and PAT growth targets.

    asked by Pratik Dharmshi

    2 min read6 chapters

    Detailed Narrative

    01

    Strong FY26 Performance Outpacing Industry Growth

    CORONA Remedies Limited reported a robust FY26, with revenue growing 17.3% YoY to INR 1,403 crores, significantly outpacing the IPM market growth of 8.6%. Adjusted PAT increased by 33.4% YoY to INR 199 crores, and EBITDA margin expanded by 80bps to 20.9%. This performance reflects consistent outperformance, with the company growing at nearly 2x the industry rate.

    02

    Strategic Acquisitions and New Market Entries

    The company successfully completed two strategic acquisitions in FY26: Wokadine, which is ranked 2 in the Indian Povidone Iodine market, and the Bayer's Portfolio, whose relaunch began in Q4 FY26. These acquisitions strengthen presence in targeted specialties and the rapidly growing infertility market. Additionally, CORONA entered the biosimilars and biologics market with the launch of three products, offering substantial long-term growth potential.

    03

    Manufacturing Capacity Expansion and International Certification

    To support growth, CORONA is expanding its manufacturing capabilities by adding a new 600-kg line and commissioning a dedicated hormone manufacturing plant, expected to be operational in Q1 or Q2 of FY27. The company also achieved EAEU GMP certification, enabling expansion into key Eurasian markets like Russia, Belarus, and Kazakhstan, further strengthening its international business.

    04

    Q4 FY26 Margin Compression Due to Growth Investments

    In Q4 FY26, EBITDA margin declined by 90bps to 17.6% from 20.9% in FY26. This was attributed to increased employee costs from the addition of two new divisions (multi-specialty and infertility) and higher R&D spend. Management emphasized these are 'growth investments' expected to yield future benefits.

    05

    Sales Force Effectiveness and Digital Adoption

    CORONA has expanded its MR strength by 450, reaching a total of 3,100, and is actively using AI for sales force effectiveness (SFE). This tool provides medical representatives with critical analytic insights for doctor interactions, new scientific indications, and ongoing knowledge, enhancing engagement with healthcare professionals. The company's PCPM (Per Capita Per Month) has increased from INR 3.62 lakhs to INR 4.11 lakhs.

    06

    Long-term Growth and Profitability Outlook

    Management reiterated its philosophy to achieve 15% revenue growth and 20% PAT growth YoY for the next 3-5 years. They expect to sustain 15% plus organic revenue growth and 25% revenue growth from acquired brands, with 20% plus PAT growth in FY27. Gross margins are targeted to be maintained at around 80% in the coming years.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.